Sino Biopharm completes RMB 1.2 billion acquisition of siRNA drugmaker Hygieia

Reuters03-30
<a href="https://laohu8.com/S/01177">Sino Biopharm</a> completes RMB 1.2 billion acquisition of siRNA drugmaker Hygieia
  • Acquisition of 100% equity interest in Hygieia completed on March 30, 2026, making Hygieia an indirect wholly owned subsidiary.
  • Hygieia financial results will be consolidated into Sino Biopharmaceutical group financial statements.
  • Deal consideration set at RMB 1.2 billion, implying 18.75x price-to-research multiple based on Hygieia 2024 R&D expense of about RMB 64 million.
  • Remaining 50% of base consideration for founding shareholders scheduled for settlement in two installments on April 29, 2028 and April 29, 2029.
  • Consideration share count was calculated using HKD/RMB exchange rate of HK$1 to RMB 0.89959.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12077387), on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment